RU2016133754A - Лечение диабета при помощи панкреатических эндокринных клеток-предшественников - Google Patents
Лечение диабета при помощи панкреатических эндокринных клеток-предшественников Download PDFInfo
- Publication number
- RU2016133754A RU2016133754A RU2016133754A RU2016133754A RU2016133754A RU 2016133754 A RU2016133754 A RU 2016133754A RU 2016133754 A RU2016133754 A RU 2016133754A RU 2016133754 A RU2016133754 A RU 2016133754A RU 2016133754 A RU2016133754 A RU 2016133754A
- Authority
- RU
- Russia
- Prior art keywords
- cells
- pancreatic endocrine
- pancreatic
- use according
- endocrine precursor
- Prior art date
Links
- 230000009996 pancreatic endocrine effect Effects 0.000 title claims 12
- 210000003890 endocrine cell Anatomy 0.000 title claims 2
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims 23
- 239000002243 precursor Substances 0.000 claims 11
- 210000001900 endoderm Anatomy 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 5
- 108091005735 TGF-beta receptors Proteins 0.000 claims 5
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims 5
- 239000008103 glucose Substances 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 229940043355 kinase inhibitor Drugs 0.000 claims 5
- 239000002609 medium Substances 0.000 claims 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 5
- 238000002054 transplantation Methods 0.000 claims 4
- 101100518002 Danio rerio nkx2.2a gene Proteins 0.000 claims 3
- 108700014808 Homeobox Protein Nkx-2.2 Proteins 0.000 claims 3
- 102100027886 Homeobox protein Nkx-2.2 Human genes 0.000 claims 3
- 101100460496 Homo sapiens NKX2-2 gene Proteins 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- LBPKYPYHDKKRFS-UHFFFAOYSA-N 1,5-naphthyridine, 2-[3-(6-methyl-2-pyridinyl)-1h-pyrazol-4-yl]- Chemical group CC1=CC=CC(C2=C(C=NN2)C=2N=C3C=CC=NC3=CC=2)=N1 LBPKYPYHDKKRFS-UHFFFAOYSA-N 0.000 claims 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims 2
- 210000000683 abdominal cavity Anatomy 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 210000000936 intestine Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 102000045246 noggin Human genes 0.000 claims 2
- 108700007229 noggin Proteins 0.000 claims 2
- 210000002747 omentum Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 210000001778 pluripotent stem cell Anatomy 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003577 pancreatic endocrine progenitor Anatomy 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0012—Cell encapsulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Claims (24)
1. Применение популяции инкапсулированных панкреатических эндокринных клеток-предшественников в производстве лекарственного средства для снижения уровня глюкозы в крови у пациента, где панкреатические эндокринные клетки-предшественники дифференцируются in vitro из клеток, экспрессирующих маркеры, характерные для линии поджелудочной энтодермы, и где панкреатические эндокринные клетки-предшественники экспрессируют NKX2.2.
2. Применение по п.1, где применение включает трансплантацию популяции инкапсулированных панкреатических эндокринных клеток-предшественников в организм пациента.
3. Применение по п.2, где применение включает трансплантацию клеток в печень, естественную поджелудочную железу, пространство под почечной капсулой, сальник, брюшную полость, субсерозное пространство, кишечник, желудок или подкожный карман.
4. Применение по п.1, где клетки получены из плюрипотентных стволовых клеток.
5. Применение по п.4, где клетки получены из эмбриональных стволовых клеток человека.
6. Применение по п.1, где панкреатические эндокринные клетки-предшественники дифференцируются in vitro из клеток, экспрессирующих маркеры, характерные для линии поджелудочной энтодермы, в среде, дополненной фактором, способным ингибировать BMP, и ингибитором киназы TGF-β рецептора I.
7. Применение по п.6, где фактором, способным ингибировать BMP, является Ноггин.
8. Применение по п.6, где ингибитором киназы TGF-β рецептора I является ингибитор II ALK5.
9. Применение по п.6, где средой является DMEM, содержащая 4500 мг/л глюкозы и 1% B27.
10. Применение по п.6, где клетки культивируют в культуральной среде приблизительно 4 дня.
11. Применение по п.1, также включающее факторы роста, антиоксиданты или противовоспалительные вещества.
12. Применение по п.1, где пациент страдает диабетом I или II типа или подвергающегося риску его развития.
13. Способ снижения уровней глюкозы в крови у пациента с помощью инкапсулированных панкреатических клеток-предшественников, экспрессирующих NKX2.2, включающий:
культивирование клеток, экспрессирующих маркеры, характерные для линии поджелудочной энтодермы, в среде, дополненной фактором, способным ингибировать BMP, и ингибитором киназы TGF-β рецептора I, для дифференцировки клеток, экспрессирующих маркеры, характерные для линии поджелудочной энтодермы в панкреатические эндокринные клетки-предшественники;
инкапсулирование панкреатических эндокринных клеток-предшественников; и
трансплантацию инкапсулированных панкреатических эндокринных клеток-предшественников в организм пациента.
14. Способ снижения уровней глюкозы в крови у пациента с помощью инкапсулированных панкреатических эндокринных клеток-предшественников, экспрессирующих NKX2.2, включающий трансплантацию инкапсулированных панкреатических эндокринных клеток-предшественников в организм пациента,
где панкреатические эндокринные клетки-предшественники получены дифференцировкой клеток, экспрессирующих маркеры, характерные для линии панкреатической эндодермы, в среде, дополненной фактором, способным ингибировать BMP, и ингибитором киназы TGF-β рецептора I, для дифференцировки клеток, экспрессирующих маркеры, характерные для линии поджелудочной энтодермы в панкреатические эндокринные клетки-предшественники.
15. Способ по п.13 или 14, где трансплантация включает трансплантацию клеток в печень, естественную поджелудочную железу, пространство под почечной капсулой, сальник, брюшную полость, субсерозное пространство, кишечник, желудок или подкожный карман.
16. Способ по п.13 или 14, где фактором, способным ингибировать BMP, является Ноггин.
17. Способ по п.13 или 14, где ингибитором киназы TGF-β рецептора I является ингибитор II ALK5.
18. Способ по п.13 или 14, где средой является DMEM, содержащая 4500 мг/л глюкозы и 1% B27.
19. Способ по п.13 или 14, где клетки, экспрессирующие маркеры, характерные для линии поджелудочной энтодермы получены из плюрипотентных стволовых клеток.
20. Способ по п.13 или 14, где клетки, экспрессирующие маркеры, характерные для линии поджелудочной энтодермы получены из человеческих эмбриональных стволовых клеток.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37310910P | 2010-08-12 | 2010-08-12 | |
| US61/373,109 | 2010-08-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013110524/15A Division RU2013110524A (ru) | 2010-08-12 | 2011-08-11 | Лечение диабета при помощи панкреатических эндокринных клеток-предшественников |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016133754A true RU2016133754A (ru) | 2018-12-10 |
| RU2016133754A3 RU2016133754A3 (ru) | 2018-12-10 |
| RU2682719C2 RU2682719C2 (ru) | 2019-03-21 |
Family
ID=45564982
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013110524/15A RU2013110524A (ru) | 2010-08-12 | 2011-08-11 | Лечение диабета при помощи панкреатических эндокринных клеток-предшественников |
| RU2016133754A RU2682719C2 (ru) | 2010-08-12 | 2011-08-11 | Лечение диабета при помощи панкреатических эндокринных клеток-предшественников |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013110524/15A RU2013110524A (ru) | 2010-08-12 | 2011-08-11 | Лечение диабета при помощи панкреатических эндокринных клеток-предшественников |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20120039955A1 (ru) |
| EP (2) | EP3981415A1 (ru) |
| JP (5) | JP2013533319A (ru) |
| KR (3) | KR20130100122A (ru) |
| CN (1) | CN103052393B (ru) |
| AR (1) | AR082674A1 (ru) |
| AU (1) | AU2011289379A1 (ru) |
| BR (1) | BR112013003160A2 (ru) |
| CA (1) | CA2807158A1 (ru) |
| DK (1) | DK2603226T3 (ru) |
| MX (1) | MX2013001673A (ru) |
| RU (2) | RU2013110524A (ru) |
| SG (2) | SG10201506264QA (ru) |
| WO (1) | WO2012021698A2 (ru) |
| ZA (1) | ZA201301836B (ru) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108220224A (zh) | 2011-06-21 | 2018-06-29 | 诺沃—诺迪斯克有限公司 | 自多潜能干细胞有效诱导定形内胚层 |
| KR102232650B1 (ko) * | 2013-06-11 | 2021-03-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | SC-β 세포 및 조성물 그리고 그 생성 방법 |
| WO2015173578A1 (en) * | 2014-05-14 | 2015-11-19 | The University Court Of The University Of Aberdeen | Methods of obtaining islet cells |
| CA2948833A1 (en) * | 2014-05-14 | 2015-11-19 | The University Court Of The University Of Aberdeen | Methods of obtaining pancreatic endocrine cells |
| DK3234110T3 (da) | 2014-12-18 | 2024-05-13 | Harvard College | FREMGANGSMÅDER TIL GENERERING AF STAMCELLE-AFLEDTE ß-CELLER OG ANVENDELSER DERAF |
| US10443042B2 (en) | 2014-12-18 | 2019-10-15 | President And Fellows Of Harvard College | Serum-free in vitro directed differentiation protocol for generating stem cell-derived beta cells and uses thereof |
| US10253298B2 (en) | 2014-12-18 | 2019-04-09 | President And Fellows Of Harvard College | Methods for generating stem cell-derived beta cells and methods of use thereof |
| JP6847044B2 (ja) * | 2015-03-11 | 2021-03-24 | シーシーエス・ベンチャーズ・リミテッド | 肥満及び２型糖尿病（ｔ２ｄ）の治療のための膵内分泌前駆細胞療法 |
| CA3042495A1 (en) * | 2016-11-10 | 2018-05-17 | Viacyte, Inc. | Pdx1 pancreatic endoderm cells in cell delivery devices and methods thereof |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| WO2019099725A1 (en) | 2017-11-15 | 2019-05-23 | Semma Therapeutics, Inc. | Islet cell manufacturing compositions and methods of use |
| AU2019320072A1 (en) | 2018-08-10 | 2021-02-25 | Vertex Pharmaceuticals Incorporated | Stem cell derived islet differentiation |
| CA3139590C (en) | 2019-05-31 | 2024-01-23 | W. L. Gore & Associates, Inc. | A biocompatible membrane composite |
| AU2020282355B2 (en) | 2019-05-31 | 2023-11-02 | Viacyte, Inc. | A biocompatible membrane composite |
| AU2020283150B2 (en) | 2019-05-31 | 2023-08-17 | Viacyte, Inc. | Cell encapsulation devices with controlled oxygen diffusion distances |
| US20220233298A1 (en) | 2019-05-31 | 2022-07-28 | W. L. Gore & Associates, Inc. | A biocompatible membrane composite |
| KR102247950B1 (ko) * | 2019-10-16 | 2021-05-04 | 가톨릭대학교 산학협력단 | 이식 후 당뇨병의 발병 위험도 예측 방법 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4557264A (en) | 1984-04-09 | 1985-12-10 | Ethicon Inc. | Surgical filament from polypropylene blended with polyethylene |
| US5863531A (en) | 1986-04-18 | 1999-01-26 | Advanced Tissue Sciences, Inc. | In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework |
| US5804178A (en) | 1986-11-20 | 1998-09-08 | Massachusetts Institute Of Technology | Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue |
| US5567612A (en) | 1986-11-20 | 1996-10-22 | Massachusetts Institute Of Technology | Genitourinary cell-matrix structure for implantation into a human and a method of making |
| CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
| GB9206861D0 (en) | 1992-03-28 | 1992-05-13 | Univ Manchester | Wound healing and treatment of fibrotic disorders |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US6224912B1 (en) * | 1996-04-03 | 2001-05-01 | The Rogo Institute | Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment |
| US6800480B1 (en) | 1997-10-23 | 2004-10-05 | Geron Corporation | Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture |
| CO4980885A1 (es) | 1997-12-29 | 2000-11-27 | Ortho Mcneil Pharm Inc | Compuestos de trifenilpropanamida utiles en el tratamiento de inflamaciones y metodos para preparar dicho compuesto |
| MY132496A (en) | 1998-05-11 | 2007-10-31 | Vertex Pharma | Inhibitors of p38 |
| US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| US6413556B1 (en) | 1999-01-08 | 2002-07-02 | Sky High, Llc | Aqueous anti-apoptotic compositions |
| JP2002538779A (ja) * | 1999-02-10 | 2002-11-19 | キュリス インコーポレイテッド | 膵臓細胞前駆細胞、それらに関する方法及び利用 |
| US6306424B1 (en) | 1999-06-30 | 2001-10-23 | Ethicon, Inc. | Foam composite for the repair or regeneration of tissue |
| US6333029B1 (en) | 1999-06-30 | 2001-12-25 | Ethicon, Inc. | Porous tissue scaffoldings for the repair of regeneration of tissue |
| EP1224259A4 (en) * | 1999-09-27 | 2005-04-27 | Univ Florida | INVERSION OF INSULIN DEPENDENT DIABETES BY ISOLATED STEM CELLS, PROGENITOR ISLANDIC CELLS, AND INSULAR TYPE STRUCTURES |
| US7439064B2 (en) | 2000-03-09 | 2008-10-21 | Wicell Research Institute, Inc. | Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium |
| US7005252B1 (en) | 2000-03-09 | 2006-02-28 | Wisconsin Alumni Research Foundation | Serum free cultivation of primate embryonic stem cells |
| US7793111B1 (en) | 2000-09-28 | 2010-09-07 | Intel Corporation | Mechanism to handle events in a machine with isolated execution |
| JP4524072B2 (ja) | 2000-10-23 | 2010-08-11 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規化合物 |
| US6599323B2 (en) | 2000-12-21 | 2003-07-29 | Ethicon, Inc. | Reinforced tissue implants and methods of manufacture and use |
| WO2002059278A2 (en) * | 2001-01-24 | 2002-08-01 | The Government Of The United States Of America, As Represented By The Secretary Of Department Of Health & Human Services | Differentiation of stem cells to pancreatic endocrine cells |
| US6656488B2 (en) | 2001-04-11 | 2003-12-02 | Ethicon Endo-Surgery, Inc. | Bioabsorbable bag containing bioabsorbable materials of different bioabsorption rates for tissue engineering |
| US6626950B2 (en) | 2001-06-28 | 2003-09-30 | Ethicon, Inc. | Composite scaffold with post anchor for the repair and regeneration of tissue |
| GB0117583D0 (en) | 2001-07-19 | 2001-09-12 | Astrazeneca Ab | Novel compounds |
| WO2003039489A2 (en) * | 2001-11-09 | 2003-05-15 | Artecel Sciences, Inc. | Endocrine pancreas differentiation of adipose tissue-derived stromal cells and uses thereof |
| JP4666567B2 (ja) | 2001-12-07 | 2011-04-06 | ジェロン・コーポレーション | ヒト胚幹細胞由来の膵島細胞 |
| US20060003446A1 (en) | 2002-05-17 | 2006-01-05 | Gordon Keller | Mesoderm and definitive endoderm cell populations |
| JP2005537803A (ja) * | 2002-09-06 | 2005-12-15 | アムサイト インコーポレーティッド | Ｃｄ５６陽性ヒト成体膵臓内分泌前駆細胞 |
| US20040062753A1 (en) | 2002-09-27 | 2004-04-01 | Alireza Rezania | Composite scaffolds seeded with mammalian cells |
| US7144999B2 (en) | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
| WO2005045001A2 (en) * | 2003-02-14 | 2005-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Insulin-producing cells derived from stem cells |
| ITRM20030395A1 (it) | 2003-08-12 | 2005-02-13 | Istituto Naz Per Le Malattie Infettive Lazz | Terreno di coltura per il mantenimento, la proliferazione e il differenziamento di cellule di mammifero. |
| US7541185B2 (en) * | 2003-12-23 | 2009-06-02 | Cythera, Inc. | Methods for identifying factors for differentiating definitive endoderm |
| US20050266554A1 (en) | 2004-04-27 | 2005-12-01 | D Amour Kevin A | PDX1 expressing endoderm |
| WO2005065354A2 (en) | 2003-12-31 | 2005-07-21 | The Burnham Institute | Defined media for pluripotent stem cell culture |
| US20080241107A1 (en) | 2004-01-23 | 2008-10-02 | Copland Iii John A | Methods and Compositions For Preparing Pancreatic Insulin Secreting Cells |
| WO2005086845A2 (en) | 2004-03-10 | 2005-09-22 | Regents Of The University Of California | Compositions and methods for growth of embryonic stem cells |
| WO2007039986A1 (ja) * | 2005-10-05 | 2007-04-12 | Osaka University | 脂肪組織由来細胞から膵内分泌細胞を得る方法 |
| AU2007224116B2 (en) * | 2006-03-02 | 2013-11-07 | Viacyte, Inc. | Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production |
| WO2009018453A1 (en) * | 2007-07-31 | 2009-02-05 | Lifescan, Inc. | Differentiation of human embryonic stem cells |
| CN101878298B (zh) * | 2007-11-27 | 2017-08-15 | 生命扫描有限公司 | 人胚胎干细胞的分化 |
| US8278106B2 (en) * | 2008-11-14 | 2012-10-02 | Viacyte, Inc. | Encapsulation of pancreatic cells derived from human pluripotent stem cells |
| US11779311B2 (en) | 2018-09-14 | 2023-10-10 | Fujifilm Sonosite, Inc. | Method and apparatus for performing spectral doppler imaging |
-
2011
- 2011-08-11 KR KR1020137005824A patent/KR20130100122A/ko active Application Filing
- 2011-08-11 CA CA2807158A patent/CA2807158A1/en active Pending
- 2011-08-11 WO PCT/US2011/047410 patent/WO2012021698A2/en active Application Filing
- 2011-08-11 SG SG10201506264QA patent/SG10201506264QA/en unknown
- 2011-08-11 DK DK11817033.1T patent/DK2603226T3/da active
- 2011-08-11 EP EP21167043.5A patent/EP3981415A1/en active Pending
- 2011-08-11 BR BR112013003160A patent/BR112013003160A2/pt not_active Application Discontinuation
- 2011-08-11 CN CN201180038871.7A patent/CN103052393B/zh active Active
- 2011-08-11 AU AU2011289379A patent/AU2011289379A1/en not_active Abandoned
- 2011-08-11 RU RU2013110524/15A patent/RU2013110524A/ru unknown
- 2011-08-11 KR KR1020197007026A patent/KR20190027969A/ko not_active Application Discontinuation
- 2011-08-11 MX MX2013001673A patent/MX2013001673A/es not_active Application Discontinuation
- 2011-08-11 RU RU2016133754A patent/RU2682719C2/ru active
- 2011-08-11 JP JP2013524228A patent/JP2013533319A/ja not_active Withdrawn
- 2011-08-11 EP EP11817033.1A patent/EP2603226B1/en active Active
- 2011-08-11 SG SG2013005921A patent/SG187603A1/en unknown
- 2011-08-11 KR KR1020187007871A patent/KR20180032674A/ko active Application Filing
- 2011-08-11 US US13/207,905 patent/US20120039955A1/en not_active Abandoned
- 2011-08-12 AR ARP110102941A patent/AR082674A1/es unknown
-
2013
- 2013-03-11 ZA ZA2013/01836A patent/ZA201301836B/en unknown
-
2016
- 2016-08-26 JP JP2016165581A patent/JP2017031163A/ja active Pending
-
2019
- 2019-03-06 JP JP2019040598A patent/JP2019131564A/ja active Pending
-
2020
- 2020-08-06 JP JP2020133922A patent/JP7012128B2/ja active Active
-
2022
- 2022-01-14 JP JP2022004689A patent/JP2022058629A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190027969A (ko) | 2019-03-15 |
| JP7012128B2 (ja) | 2022-01-27 |
| EP2603226B1 (en) | 2021-04-07 |
| JP2020196728A (ja) | 2020-12-10 |
| EP2603226A4 (en) | 2014-01-15 |
| RU2682719C2 (ru) | 2019-03-21 |
| WO2012021698A3 (en) | 2012-05-10 |
| CN103052393B (zh) | 2017-11-14 |
| SG10201506264QA (en) | 2015-09-29 |
| WO2012021698A2 (en) | 2012-02-16 |
| JP2013533319A (ja) | 2013-08-22 |
| US20120039955A1 (en) | 2012-02-16 |
| CN103052393A (zh) | 2013-04-17 |
| AU2011289379A1 (en) | 2013-02-07 |
| EP3981415A1 (en) | 2022-04-13 |
| DK2603226T3 (da) | 2021-06-07 |
| KR20180032674A (ko) | 2018-03-30 |
| JP2017031163A (ja) | 2017-02-09 |
| JP2019131564A (ja) | 2019-08-08 |
| MX2013001673A (es) | 2013-03-25 |
| ZA201301836B (en) | 2018-12-19 |
| CA2807158A1 (en) | 2012-02-16 |
| JP2022058629A (ja) | 2022-04-12 |
| SG187603A1 (en) | 2013-03-28 |
| AR082674A1 (es) | 2012-12-26 |
| BR112013003160A2 (pt) | 2016-06-28 |
| RU2013110524A (ru) | 2014-09-20 |
| EP2603226A2 (en) | 2013-06-19 |
| RU2016133754A3 (ru) | 2018-12-10 |
| KR20130100122A (ko) | 2013-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016133754A (ru) | Лечение диабета при помощи панкреатических эндокринных клеток-предшественников | |
| ES2932850T3 (es) | Encapsulación de células pancreáticas derivadas de células madre pluripotentes humanas | |
| US10927350B2 (en) | Methods for generating stem cell-derived beta cells and uses thereof | |
| ES2968078T3 (es) | Medios de cultivo para células madre | |
| Borowiak et al. | How to make β cells? | |
| RU2017102194A (ru) | Дифференцировка человеческих эмбриональных стволовых клеток | |
| KR102519502B1 (ko) | 만능성 줄기 세포의 현탁 배양 | |
| RU2014130042A (ru) | Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки | |
| RU2010107224A (ru) | Дифференцировка человеческих эмбриональных стволовых клеток | |
| WO2016100925A1 (en) | METHODS FOR GENERATING AUGMENTED STEM CELL-DERIVED β CELLS AND USES THEREOF | |
| RU2014149185A (ru) | Дифференцирование эмбриональных стволовых клеток человека в панкреатическую энтодерму | |
| MX2009004640A (es) | Estimulacion por litio de proliferacion de celula de tallo sanguinea de cordon y produccion de factor de crecimiento. | |
| RU2018139710A (ru) | Дифференцировка плюрипотентных стволовых клеток в клетки кишечной энтодермы средней кишки | |
| KR101690872B1 (ko) | 편도 유래 중간엽 줄기세포로부터 인슐린 분비 세포의 분화 방법 | |
| Stanekzai et al. | Treatment options for diabetes: potential role of stem cells | |
| WO2006107850A3 (en) | Preventing rejection of transplanted tissue using regulatory t cells | |
| AU2016228894B2 (en) | Pancreatic endocrine progenitor cell therapies for the treatment of obesity and Type 2 diabetes (T2D) | |
| Samuelson et al. | Improved function and growth of pancreatic cells in a three-dimensional bioreactor environment | |
| BR112020004428A2 (pt) | métodos de criopreservação de agregados de células endócrinas pancreáticas e de enriquecimento de agregados de células endócrinas, células endócrinas, composição contendo células endócrinas, medicamento, e, dispositivo. | |
| CN105062952A (zh) | 间充质干细胞转化为胰岛细胞的方法 | |
| BR112016013623B1 (pt) | Método de preparação de uma estrutura de célula esferoide semelhante à ilhota pancreática cultivada artificialmente, e uso de uma estrutura de célula esferoide | |
| JP6453753B2 (ja) | 脂肪組織細胞 | |
| CN108841779A (zh) | 胰腺特异性ECM在促进BMSCs增殖、迁移及定向分化为胰岛素分泌细胞中的应用 | |
| Wilson | Human β-cell proliferation by promoting Wnt signalling | |
| JP7369347B2 (ja) | インスリン産生細胞の製造方法 |